Literatur
- 1
Bartl R.
Auf dem Weg zu einer rationalen Therapiedauer mit Bisphosphonaten.
Dtsch Med Wochenschr.
2007;
132
(11)
545
- 2 Bartl R. Osteoporose – Prävention, Diagnostik, Therapie.
3. Aufl. Stuttgart; Thieme 2008
- 3 Bartl R, Frisch B, von Tresckow E, Bartls C. Bisphosphonates in medical
practice. Heidelberg; Springer 2007
- 4
Black D, Bilezikian J, Ensrud K. et al .
One year of alendronate after one year
of parathyroid hormone (1 – 84) for osteoporosis.
N Engl J Med.
2005;
353
555-565
- 5
Black D, Delmas P, Eastell R. et
al .
Once-yearly zoledronic acid for treatment of postmenopausal
osteoporosis.
N Engl J Med.
2007;
356
1809-1822
- 6
Black D, Schwartz A, Ensrud K.
Effects of continuing or stopping alendronate after 5 years
of treatment. The fracture intervention trial long-term extension
(FLEX): a randomized trial.
JAMA.
2006;
296
2927-2938
- 7
Bone H, Hosking D, Devogelaer J -P. et
al .
Ten years’ experience with alendronate
for osteoporosis in postmenopausal women.
N Engl J Med.
2004;
350
1189-1199
- 8 Fleisch H. Bisphosphonates in Bone Disease. 4th Ed. San Diego; Academic Press 2000
- 9
Lyles K. et
al .
Zoledronic acid and clinical fractures and mortality
after hip fracture.
N Engl J Med.
2007;
357
1799-1809
- 10
Nancollas G, Tang R. et al .
Mineral
binding affinities and zeta potentials of bisphosphonates.
J
Bone Miner Res.
2002;
17
(S1)
5368
- 11
Russell R, Watts N, Ebentino F, Rogers M.
Mechanisms of action of bisphosphonates:
similarities and differences and their potential influence on clinical
efficacy.
Osteoporos Int.
2008;
19
733-759
Prof. Dr. med. R. Bartl
Bayerisches Osteoporose-Zentrum der Universität
München, Klinikum der Universität, Großhadern
Marchioninistr. 15
81377 München
Phone: 089/7095-2520
Fax: 089/7095-5514
Email: Reiner.Bartl@med.uni-muenchen.de
